Molecular signatures at baseline and post-vaccine predict humoral immunogenicity of a GLA-SE adjuvanted gp120 HIV vaccine in infants.

Kinga K. Smolen, Boston Children's Hospital, Boston, MA, United States; Joann Diray-Arce, Boston Children's Hospital, Boston, MA, United States; Annmarie Hoch, Boston Children's Hospital, Cambridge, MA, United States; Thomas Kouyate, Boston Children's Hospital, Boston, MA, United States; Caitlin Syphurs, Boston Children's Hospital, Boston, MA, United States; Jing Chen, Boston Children's Hospital, Boston, MA, United States; Dylan Nicholas Tabang, Boston Children’s Hospital & Harvard Medical School, Boston, MA, United States; Athena Nguyen, Boston Children's Hospital, Washington, DC, United States; Alec Plotkin, Boston Children's Hospital, Morrisville, NC, United States; Jensen Pak, Boston Children's Hospital, Boston, MA, United States; Asimenia Angelidou, Harvard Medical School, Boston, MA, United States; Al Ozonoff, Harvard Medical School, Boston, MA, United States; Tobias R. Kollmann, Dalhousie University, Halifax, NS, Canada; Scott Tebbutt, UBC, Vancouver, BC, Canada; William Hahn, University of Washington, Seattle, Seattle, WA, United States; Holly Janes, Fred Hutchinson Cancer Center, Seattle, WA, United States; Troy M. Martin, Fred Hutch Cancer Center, Seattle, WA, United States; David Martino, The Kids Research Institute Australia, Perth, Western Australia, Australia; Hanno Steen, Boston Children's Hospital, Boston, MA, United States; Ofer Levy, Precision Vaccines Program, Boston Children's Hospital, Boston, MA, United States